A panel of physicians, biotech leaders and patient advocates took aim at the FDA during a Senate hearing Thursday on how the ...
Quotient Sciences, a CDMO that specializes in "niche and smaller volume" drugs that it says are often overlooked by bigger contract manufacturers, has ...
RGX-121 was rejected in early February, with Regenxbio listing the primary reasons given by the FDA as concerns about the ability to properly define a patient population, the use of a natural history ...
This article is part of a Rare Disease series sponsored by DeepIntent. With Rare Disease Month wrapping up and Rare Disease Day taking place on Saturday, MM+M is celebrating a handful of campaigns ...
This week’s Capitol Hill meetings come on the heels of rejections of ultra-rare disease drugs developed by Biohaven and Saol Therapeutics. Physicians and patient groups implored the FDA to expedite ...
Bridging Nations. Accelerating Therapies for Rare Diseases Together. The organization’s 2030 vision institutionalizes ...
The U.S. Senate unanimously approved a bipartisan resolution declaring Feb. 28, 2026, as Rare Disease Day, aiming to expand ...
Recurrent respiratory papillomatosis (RRP) treatment finally approved by FDA, targeting the root cause of the disease and ...
Just days after her son was born, Julia Friar learned he had galactosemia, a rare genetic disorder that can be ...
Rare Disease Day is held on the last day of February to raise awareness for rare diseases and address drug development ...
Today is Rare Disease Day and it's meant to raise awareness for patients and families dealing with rare dieseases.
A Colorado family is calling for change and sharing their struggle after a clinical trial their son relied on suddenly ended.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results